Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
about
Second and third line treatment options for Helicobacter pylori eradicationHelicobacter pylori infection in JapanIn vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pyloriEfficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies.A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori EradicationRifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.Attempts to enhance the eradication rate of Helicobacter pylori infectionQuinolone-containing therapies in the eradication of Helicobacter pyloriMechanisms of Helicobacter pylori antibiotic resistance and molecular testing.Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori.Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea.Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens.Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial
P2860
Q26829666-98A7A6B3-B08C-4D94-8BB6-0AE803A76320Q27010197-380B8712-13D8-477B-A93D-C1FAADC0F202Q28534899-834C56AB-F01E-424A-AFE8-2AC14FAED570Q36979151-69830670-72AD-4F78-B242-063900001807Q36993414-C1904935-1FC5-4DFA-BC8C-4692096127E3Q37045762-FDFB6624-1982-4580-B875-C2A454F86DF2Q38212213-989CB1DB-E0C3-4CCE-BEC9-8F032C3CAEBEQ38253054-04680DB4-73F6-4129-AB5D-895A69E12F9BQ38490776-7F14FDFF-BBEB-4533-80F2-C12890BC3DADQ38496942-3D9C7B59-81F9-4611-A83C-BC49C621F5CDQ39014376-CAD81CC6-0661-4CDB-B3E3-7BC88E41636AQ39496571-D0A6E566-37C6-4048-97C2-7D0977E13072Q39496596-B63C9D02-C530-45EE-AF12-A596ACDCC1A3Q40892650-AD535921-F0A3-4E70-8419-AB43DE81301CQ41680509-2DDF2933-BBDE-472C-B33F-944C06BFE4F2Q42284208-4827E743-AB0A-405E-9BEE-AE64424A0807Q43423723-021FEDD6-1598-4293-8B84-3C355F7C0F15Q48600558-96A4EB98-DFB8-4F93-BC30-921E53F17FFEQ54945494-054DCE31-9D13-408F-B743-EFAEDE0508E1Q57224739-7C2F3DE9-449A-4309-85C3-0BA9E71BE0E0
P2860
Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Efficacy of sitafloxacin-based ...... st- and second-line therapies.
@ast
Efficacy of sitafloxacin-based ...... st- and second-line therapies.
@en
type
label
Efficacy of sitafloxacin-based ...... st- and second-line therapies.
@ast
Efficacy of sitafloxacin-based ...... st- and second-line therapies.
@en
prefLabel
Efficacy of sitafloxacin-based ...... st- and second-line therapies.
@ast
Efficacy of sitafloxacin-based ...... st- and second-line therapies.
@en
P2093
P2860
P356
P1476
Efficacy of sitafloxacin-based ...... rst- and second-line therapies
@en
P2093
Hidekazu Suzuki
Kenro Hirata
Sawako Okada
Seiichiro Fukuhara
Toshifumi Hibi
Toshihiro Nishizawa
Yoshimasa Saito
P2860
P304
P356
10.1128/AAC.05941-11
P407
P577
2011-12-27T00:00:00Z